Acute lymphoblastic leukemia (ALL) is a challenging cancer, especially when it relapses or becomes resistant to treatment (R/R). This article examines the FDA-approved drug inotuzumab ozogamicin, a significant advancement in treating pediatric R/R B-cell ALL, and explores the evolving therapeutic landscape for this disease. Understanding Acute Lymphoblastic Leukemia (ALL) ALL is a heterogeneous disease marked […]